Press Releases Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:32:45 14/07/2026 BST			5-day change	1st Jan Change
5.660 ^USD	-1.39%		-7.42%	-4.81%

06-23	Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing	MT
06-08	Savara Inc. Announces CFO Changes	CI

Press Releases

06-12	Savara Announces New Employment Inducement Grant	BU
06-08	Savara Announces Chief Financial and Administrative Officer Transition	BU
05-27	Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference	BU
05-20	Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026	BU
05-19	Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	BU
05-18	Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	BU
05-12	Savara Reports First Quarter Financial Results and Provides Business Update	BU
05-11	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference	BU
04-17	Savara Announces New Employment Inducement Grant	BU
04-15	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
04-14	Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference	BU
04-08	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency Has Accepted the MOLBREEVI Marketing Authorisation Application for Autoimmune Pulmonary Alveolar Proteinosis	AQ
04-07	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
03-30	Savara : Corporate Presentation	PU
03-30	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
03-13	Savara : Corporate Presentation	PU
03-13	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update	BU
03-09	Savara Provides Regulatory Update on the MOLBREEVI Development Program in Autoimmune Pulmonary Alveolar Proteinosis	AQ
03-06	Savara : Corporate Presentation	PU
03-06	Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
03-04	Savara Announces Participation in 2026 Citizens Life Sciences Conference	BU
02-20	Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
02-16	Savara Announces New Employment Inducement Grant	AQ
02-13	Savara Announces New Employment Inducement Grant	BU
02-04	Savara Announces Participation in Upcoming Investor Healthcare Conferences	BU